MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
February 24, 2026
Technology
-
-
Treasure Global Reports Second Quarter Year 2026 Financial Results
February 24, 2026
-
X3 Holdings Expands Into AI Healthcare Through Strategic Smartwatch Partnership
February 24, 2026
-
SEALSQ Deepens Technology Focus on CMOS-Compatible Quantum Architectures to Enable Secure Scalable Silicon-Based Quantum Computing
February 24, 2026
-
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
-
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
February 24, 2026
-
Amtech Announces Participation in March 2026 Investor Events
February 24, 2026
-
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
February 24, 2026
-
Intchains Group Limited Accelerates ETH Accumulation and Staking Strategy
February 24, 2026
-
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
February 24, 2026
-
Accelerated Engineering Software and Certified Composite Production Capturing Share of $100B+ Aerospace Market
February 24, 2026
-
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
February 23, 2026
-
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
February 23, 2026
-
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
February 23, 2026
-
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
February 23, 2026
-
Broadridge to Participate in Upcoming Investor Events
February 23, 2026